IMMunological ResPonse Assessment AfteR Acute ISchemic Stroke Treated with Endovascular Therapy (IMPRESS)

Launched by FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD · Dec 10, 2020

Keywords

ClinConnect Summary

The IMPRESS trial is studying how the body's immune system responds in the first 24 to 36 hours after a person has an acute ischemic stroke, which is a type of stroke caused by a blocked blood vessel in the brain. Specifically, the trial focuses on patients who are receiving a treatment called mechanical thrombectomy, a procedure that helps remove the blockage. Researchers want to understand how the immune response during this critical time might affect recovery and overall function three months after the stroke.

To participate in the trial, individuals need to be between the ages of 65 and 87 and must have a confirmed acute ischemic stroke that requires mechanical thrombectomy based on medical guidelines. However, those with certain conditions, such as bleeding in the brain, pre-existing severe disabilities, or who are pregnant or breastfeeding, cannot join. Participants will be monitored closely during their treatment, and their health outcomes will be assessed at three months to see how well they are recovering. This study aims to provide valuable insights into stroke recovery and improve treatment strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed,
• • Having received informed information about the study and having signed a consent to participate in the study (if this is not possible: information and consent of the trusted support person or family member if present; emergency inclusion if absent);
• • Affiliated or beneficiary of a social security scheme or equivalent.
• Non inclusion Criteria:
• • Pregnant or breast-feeding women
• • Patient benefiting from a legal protection measure
• Exclusion Criteria:
• • None.